Decision-making in ileocecal Crohns disease management: Surgery versus pharmacotherapy

Expert Review of Gastroenterology and Hepatology

Volumn 4, Issue 2, 2010, Pages 181-189

  Eshuis, Emma J ^a   Stokkers, Pieter Cf ^a   Bemelman, Willem A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Biologic therapy; Clinical remission; Crohns disease; Decision making; Ileocecal disease activity; Ileocolic resection

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; PREDNISONE;

CLINICAL DECISION MAKING; COLON RESECTION; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG COST; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; EARLY INTERVENTION; ENTERITIS; HUMAN; ILEOCOLIC RESECTION; INFECTION; LAPAROSCOPIC SURGERY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; THERAPY DELAY; ABDOMINAL SURGERY; ALGORITHM; CECUM; DECISION MAKING; DRUG EFFECT; DRUG THERAPY; ECONOMICS; ILEUM;

ALGORITHMS; CECUM; CROHN DISEASE; DECISION MAKING; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DRUG THERAPY; HUMANS; ILEUM;

EID: 77950482085     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.10.3     Document Type: Review

References (64)

1. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel Dis. 12(Suppl. 1), S3-S9 (2006). (Pubitemid 43068428)
2. Rutgeerts PJ. An historical overview of the treatment of Crohn's disease: why do we need biological therapies? Rev. Gastroenterol. Disord. 4(Suppl. 3), S3-S9 (2004).
3. Goldstein F. Immunosuppressant therapy of inflammatory bowel disease. Pharmacologic and clinical aspects. J. Clin. Gastroenterol. 9, 654-658 (1987). (Pubitemid 18055988)
4. Andrews JM, Travis SP, Gibson PR, Gasche C. Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? Aliment. Pharmacol. Ther. 29, 459-469 (2009).
5. Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 28, 674-688 (2008).
6. Yun L, Hanauer S. Selecting appropriate anti-TNF agents in inflammatory bowel disease. Expert Rev. Gastroenterol. Hepatol. 3, 235-248 (2009).
7. Alos R, Hinojosa J. Timing of surgery in Crohn's disease: a key issue in the management. World J. Gastroenterol. 14, 5532-5539 (2008).
8. Hyman NH. Crohn's disease: drug therapy or surgery? Expert Rev. Gastroenterol. Hepatol. 1, 187-192 (2007).
9. Shariff U, Narula H, Speake W, Brown S. Terminal ileal Crohn's disease: conservative surgeon and aggressive physician? Colorectal Dis. 11, 522-523 (2009).
10. Travis SP, Stange EF, Lemann M et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55 (Suppl. 1), i16-i35 (2006). (Pubitemid 43268291)
11. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130, 935-939 (2006). (Pubitemid 43374542)
12. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am. J. Gastroenterol. 104, 465-483 (2009).
13. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis. J. Am. Med. Assoc. 1323-1329 (1932).
14. Freeman HJ. Application of the Montreal classification for Crohn's disease to a single clinician database of 1015 patients. Can. J. Gastroenterol. 21, 363-366 (2007).
15. Hyman NH, Fazio VW. Crohn's disease of the small bowel. Compr. Ther. 17, 38-42 (1991).
16. D'Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371, 660-667 (2008). (Pubitemid 351284485)
17. Herfarth H. Are we ready for top-down therapy for inflammatory bowel diseases: con. Expert. Rev. Gastroenterol. Hepatol. 1, 249-255 (2007).
18. van der Woude CJ, Hommes DW. Are we ready for top-down therapy for inflammatory bowel diseases: pro. Expert Rev. Gastroenterol. Hepatol. 1, 243-248 (2007).
19. Wong K, Bressler B. Mild to moderate Crohn's disease: an evidence-based treatment algorithm. Drugs 68, 2419-2425 (2008).
20. Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 16(3), CD000296 (2008).
21. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 21(1), CD000067 (2009).
22. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37, 674-678 (1995).
23. Feagan BG, Fedorak RN, Irvine EJ et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N. Engl. J. Med. 342, 1627-1632 (2000). (Pubitemid 30341531)
24. Feagan BG, Rochon J, Fedorak RN et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N. Engl. J. Med. 332, 292-297 (1995).
25. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337, 1029-1035 (1997).
26. Rutgeerts P, D'Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117, 761-769 (1999). (Pubitemid 29468216)
27. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359, 1541-1549 (2002). (Pubitemid 34621118)
28. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130, 323-333 (2006).
29. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132, 52-65 (2007). (Pubitemid 46108762)
30. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56, 1232-1239 (2007). (Pubitemid 47300424)
31. Behm BW, Bickston SJ. Tumor necrosis factor-a antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 23(1), CD006893 (2008).
32. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348, 601-608 (2003). (Pubitemid 36204954)
33. Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med. 146, 829-838 (2007). (Pubitemid 351650483)
34. Toruner M, Loftus EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134, 929-936 (2008). (Pubitemid 351451967)
35. Beaugerie L, Brousse N, Bouvier AM et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374, 1617-1625 (2009).
36. Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut 56, 1181-1183 (2007).
37. van Assche G, Vermeire S, Rutgeerts P. Immunosuppression in inflammatory bowel disease: traditional, biological or both? Curr. Opin. Gastroenterol. 25, 323-328 (2009).
38. Deshpande AR, Abreu MT. Combination therapy with infliximab and immunomodulators: is the glass half empty? Gastroenterology 134, 2161-2163 (2008).
39. Vermeire S, Noman M, van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 56, 1226-1231 (2007). (Pubitemid 47300423)
40. Colombel JF, Rutgeerts P, Reinisch W et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. J. Crohn Colitis 3, S45-S46 (2009).
41. Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T-cell lymphoma in inflammatory bowel disease. Gut 57, 1639-1641 (2008).
42. van Assche G, Magdelaine-Beuzelin C, D'Haens G et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134, 1861-1868 (2008). (Pubitemid 351790744)
43. Louis E, Vernier-Massouille G, Grimaud JC et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing patient cohort. Gastroenterology 136, A-146 (2009).
44. Bernklev T, Jahnsen J, Schulz T et al. Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis. Eur. J. Gastroenterol. Hepatol. 17, 1037-1045 (2005). (Pubitemid 41423996)
45. Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR. The effects of infliximab maintenance therapy on health-related quality of life. Am. J. Gastroenterol. 98, 2232-2238 (2003). (Pubitemid 37305364)
46. Loftus EV, Feagan BG, Colombel JF et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am. J. Gastroenterol. 103, 3132-3141 (2008).
47. Casellas F, Rodrigo L, Nino P, Pantiga C, Riestra S, Malagelada JR. Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years. Inflamm. Bowel. Dis. 13, 1395-1400 (2007). (Pubitemid 350206852)
48. Bodger K, Kikuchi T, Hughes D. Cost- effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment. Pharmacol. Ther. 30(3), 265-274 (2009).
49. Maartense S, Dunker MS, Slors JF et al. Laparoscopic-assisted versus open ileocolic resection for Crohn's disease: a randomized trial. Ann. Surg. 243, 143-149 (2006). (Pubitemid 43185431)
50. Milsom JW, Hammerhofer KA, Bohm B, Marcello P, Elson P, Fazio VW. Prospective, randomized trial comparing laparoscopic vs. conventional surgery for refractory ileocolic Crohn's disease. Dis. Colon Rectum 44, 1-8 (2001). (Pubitemid 32105868)
51. Polle SW, Wind J, Ubbink DT, Hommes DW, Gouma DJ, Bemelman WA. Short-term outcomes after laparoscopic ileocolic resection for Crohn's disease. A systematic review. Dig. Surg. 23, 346-357 (2006). (Pubitemid 46269283)
52. Lesperance K, Martin MJ, Lehmann R, Brounts L, Steele SR. National trends and outcomes for the surgical therapy of ileocolonic Crohn's disease: a population-based analysis of laparoscopic vs. open approaches. J. Gastrointest. Surg. 13, 1251-1259 (2009).
53. Subramanian V, Pollok RC, Kang JY, Kumar D. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br. J. Surg. 93, 793-799 (2006). (Pubitemid 44035250)
54. Appau KA, Fazio VW, Shen B et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J. Gastrointest. Surg. 12, 1738-1744 (2008).
55. Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J. Gastrointest. Surg. 12, 1730-1736 (2008).
56. Stocchi L, Milsom JW, Fazio VW. Long-term outcomes of laparoscopic versus open ileocolic resection for Crohn's disease: follow-up of a prospective randomized trial. Surgery 144, 622-627 (2008).
57. Eshuis EJ, Slors JF, Stokkers PC et al. Long-term results after laparoscopic-assisted versus open ileocolic resection for Crohn's disease. Br. J. Surg 97(4), 563-568 (2010).
58. Young-Fadok TM, HallLong K, McConnell EJ, Gomez Rey G, Cabanela RL. Advantages of laparoscopic resection for ileocolic Crohn's disease. Improved outcomes and reduced costs. Surg. Endosc. 15, 450-454 (2001). (Pubitemid 32448846)
59. Aratari A, Papi C, Leandro G, Viscido A, Capurso L, Caprilli R. Early versus late surgery for ileo-caecal Crohn's disease. Aliment. Pharmacol. Ther. 26, 1303-1312 (2007). (Pubitemid 350045607)
60. Tekkis PP, Nicholls RJ. Early or late surgery for patients with ileocecal Crohn's disease? Nat. Clin. Pract. Gastroenterol. Hepatol. 5, 304-305 (2008). (Pubitemid 351803599)
61. Scott NA, Hughes LE. Timing of ileocolonic resection for symptomatic Crohn's disease - the patient's view. Gut 35, 656-657 (1994). (Pubitemid 24163793)
62. Eshuis EJ, Bemelman WA, van Bodegraven AA et al. Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial). BMC Surg. 8, 15 (2008).
63. Weersma RK, Stokkers PC, Cleynen I et al. Confirmation of multiple Crohn's disease susceptibility loci in a large Dutch-Belgian cohort. Am. J. Gastroenterol. 104, 630-638 (2009).
64. Rutgeerts P, Vermeire S, van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 136, 1182-1197 (2009).